Market Cap (In AUD)
78.44 Million
Revenue (In AUD)
-
Net Income (In AUD)
-17.66 Million
Avg. Volume
213.56 Thousand
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.38-0.695
- PE
- -3.22
- EPS
- -0.09
- Beta Value
- 1.135
- ISIN
- AU000000RCE5
- CUSIP
- Q8052V103
- CIK
- -
- Shares
- 270517000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. James Hamilton-Bray Graham GAICD
- Employee Count
- -
- Website
- https://www.recce.com.au
- Ipo Date
- 2016-01-14
- Details
- Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
More Stocks
-
ORKT
-
CVO
-
ARQQArqit Quantum Inc.
ARQQ
-
TOGITurnOnGreen, Inc
TOGI
-
STRRP
-
EIQEcho IQ Limited
EIQ
-
SFM
-
APEX